A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

NCT01986491 ↗

Phase 1 Completed 20 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to compare the pharmacokinetics (what a medication does to the body), dose-proportionality, safety and tolerability of JNJ 39393406 following single dose oral administration of two solid oral formulations in Part 1; based on the profile in Part 1, one of the formulations assessed will be selected to investigate the pharmacokinetics in fasting condition in Part 2 and after repeated dosing in Part 3.

Timeline

Start: 2009-05
Primary completion: 2009-08
Completion: 2009-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-39393406	Small molecule	30 mg	Oral
Subject	JNJ-39393406	Small molecule	30 mg/ml	Oral
Subject	JNJ-39393406	Small molecule	120 mg	Oral

Indications

No indication recorded.